Cuba expands clinical trial of vaccine against prostate cancer

The Heberprovac vaccine was scientifically tested and approved from 2007 to 2011, since then it has passed two clinical trials, with 8 and 50 volunteers, respectively.

According to Cuba's state news agency ACN, the Center for Genetics and Biotechnology (CIGB) will expand its clinical trial of the next stage prostate cancer vaccine called Heberprovac from the first quarter of this year. after.

Picture 1 of Cuba expands clinical trial of vaccine against prostate cancer
Heberprovac vaccine was scientifically tested and approved from 2007 to 2011. (Artwork: radiogritodebaire.icrt.cu).

A reporter at La Habana led the ACN news agency that the Heberprovac vaccine was scientifically tested and approved from 2007 to 2011, and since then the vaccine has passed two clinical trials, respectively with 8 and 50 patients volunteered.

In the next trial, the first self-developed Cuban prostate vaccine will be administered to 300 patients.

It is expected that the first course of treatment with Heberprovac lasts 5 months with 7 injections, after which the patients will undergo chemotherapy, then monitored by the scientists and evaluated on a case-by-case basis before deciding on the regimen. Further treatment with this vaccine.

The CIGB team expects that Heberprovac will prove effective in stimulating the immune system, regulating hormone concentration and thereby controlling the development of the disease as the highest cause of death. for men in Cuba.

To assess the effectiveness of Heberprovac, CIGB will consult with Degarelix, which is currently considered one of the best post-prostate cancer treatment drugs in the world and is provided under the brand Ferring Pharmaceuticals. Firmagon.

If the desired effect is achieved, especially in reducing complications and side effects, Heberprovac will be produced on a large scale to provide Cuba's free national health system, and proceed to export. password.

Biotechnology and pharmaceutical products are among Cuba's key exports, with CIGB playing an important role.

The center is the author of CimaVax - the world's first lung cancer special vaccine and Heberprot-P - a medicine for the treatment of necrosis to leg complications from diabetes, as well as a number of vaccines to treat tumors. Solid tumors, skin cancer, hepatitis B, arthritis and ischemia.

  • Omega-3 helps inhibit prostate cancer
  • Prostate cancer: Treatment or no treatment?

Suggestions : prostate cancer, cancer in men, Heberprovac vaccine, heberprovac vaccine test, prostate cancer vaccine